Logo image of NPTH.CA

NEUPATH HEALTH INC (NPTH.CA) Stock Fundamental Analysis

TSX-V:NPTH - TSX Venture Exchange - CA64133P1009 - Common Stock - Currency: CAD

0.2  -0.01 (-4.76%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NPTH. NPTH was compared to 17 industry peers in the Health Care Providers & Services industry. While NPTH seems to be doing ok healthwise, there are quite some concerns on its profitability. NPTH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NPTH has reported negative net income.
In the past year NPTH had a positive cash flow from operations.
In the past 5 years NPTH always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: NPTH reported negative operating cash flow in multiple years.
NPTH.CA Yearly Net Income VS EBIT VS OCF VS FCFNPTH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 2M -2M -4M

1.2 Ratios

With a Return On Assets value of -2.05%, NPTH perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
Looking at the Return On Equity, with a value of -3.92%, NPTH is in line with its industry, outperforming 50.00% of the companies in the same industry.
NPTH's Return On Invested Capital of 2.55% is in line compared to the rest of the industry. NPTH outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -2.05%
ROE -3.92%
ROIC 2.55%
ROA(3y)-5.25%
ROA(5y)-8.14%
ROE(3y)-10.67%
ROE(5y)-20.93%
ROIC(3y)N/A
ROIC(5y)N/A
NPTH.CA Yearly ROA, ROE, ROICNPTH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

Looking at the Operating Margin, with a value of 1.61%, NPTH is in line with its industry, outperforming 43.75% of the companies in the same industry.
NPTH has a Gross Margin of 19.04%. This is in the lower half of the industry: NPTH underperforms 68.75% of its industry peers.
NPTH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.61%
PM (TTM) N/A
GM 19.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.03%
GM growth 5Y-1.85%
NPTH.CA Yearly Profit, Operating, Gross MarginsNPTH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NPTH is destroying value.
The number of shares outstanding for NPTH has been increased compared to 1 year ago.
Compared to 5 years ago, NPTH has more shares outstanding
Compared to 1 year ago, NPTH has an improved debt to assets ratio.
NPTH.CA Yearly Shares OutstandingNPTH.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
NPTH.CA Yearly Total Debt VS Total AssetsNPTH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of 1.30, we must say that NPTH is in the distress zone and has some risk of bankruptcy.
NPTH's Altman-Z score of 1.30 is in line compared to the rest of the industry. NPTH outperforms 50.00% of its industry peers.
The Debt to FCF ratio of NPTH is 5.54, which is a neutral value as it means it would take NPTH, 5.54 years of fcf income to pay off all of its debts.
NPTH has a Debt to FCF ratio of 5.54. This is in the better half of the industry: NPTH outperforms 62.50% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that NPTH is not too dependend on debt financing.
NPTH has a better Debt to Equity ratio (0.49) than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 5.54
Altman-Z 1.3
ROIC/WACC0.43
WACC5.87%
NPTH.CA Yearly LT Debt VS Equity VS FCFNPTH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M 20M

2.3 Liquidity

NPTH has a Current Ratio of 1.13. This is a normal value and indicates that NPTH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.13, NPTH is in line with its industry, outperforming 56.25% of the companies in the same industry.
NPTH has a Quick Ratio of 1.13. This is a normal value and indicates that NPTH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.13, NPTH is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
NPTH.CA Yearly Current Assets VS Current LiabilitesNPTH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.27% over the past year.
The Revenue has grown by 8.19% in the past year. This is quite good.
NPTH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.48% yearly.
EPS 1Y (TTM)52.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-206.6%
Revenue 1Y (TTM)8.19%
Revenue growth 3Y11.54%
Revenue growth 5Y10.48%
Sales Q2Q%9.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NPTH.CA Yearly Revenue VS EstimatesNPTH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
NPTH.CA Yearly EPS VS EstimatesNPTH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 0 0.02 -0.02 0.04 0.06

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NPTH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPTH.CA Price Earnings VS Forward Price EarningsNPTH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NPTH is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
87.50% of the companies in the same industry are more expensive than NPTH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 5.2
EV/EBITDA 5.76
NPTH.CA Per share dataNPTH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NPTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUPATH HEALTH INC

TSX-V:NPTH (2/21/2025, 7:00:00 PM)

0.2

-0.01 (-4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-14 2024-11-14
Earnings (Next)03-13 2025-03-13
Inst Owners24.33%
Inst Owner ChangeN/A
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap11.24M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF 5.2
P/OCF 3.8
P/B 0.52
P/tB 61.09
EV/EBITDA 5.76
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY19.22%
OCF(TTM)0.05
OCFY26.33%
SpS1.26
BVpS0.39
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.05%
ROE -3.92%
ROCE 3.54%
ROIC 2.55%
ROICexc 2.77%
ROICexgc 10.15%
OM 1.61%
PM (TTM) N/A
GM 19.04%
FCFM 3.05%
ROA(3y)-5.25%
ROA(5y)-8.14%
ROE(3y)-10.67%
ROE(5y)-20.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.03%
GM growth 5Y-1.85%
F-Score6
Asset Turnover1.7
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 5.54
Debt/EBITDA 2.96
Cap/Depr 32.65%
Cap/Sales 1.13%
Interest Coverage 4.52
Cash Conversion 82.52%
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z 1.3
F-Score6
WACC5.87%
ROIC/WACC0.43
Cap/Depr(3y)29.87%
Cap/Depr(5y)19.28%
Cap/Sales(3y)1.29%
Cap/Sales(5y)0.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-206.6%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.19%
Revenue growth 3Y11.54%
Revenue growth 5Y10.48%
Sales Q2Q%9.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y253.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y535.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y168.27%
OCF growth 3YN/A
OCF growth 5YN/A